Advanced Small Animal Ultrasound Imaging - Vevo F2

先进的小动物超声成像 - Vevo F2

• 批准号: 10632878
• 负责人: Timothy McKinsey
• 金额: $ 45.47万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-05 至 2024-06-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10632878
• 关键词: Animals; Applications Grants; Area; Basic Science; Biomedical Research; Blood Vessels; Blood flow; Cardiac; Cardiology; Cardiorenal syndrome; Cardiovascular Models; Cardiovascular system; Cells; Clinical; Collaborations; Colorado; Core Facility; Data; Disease; Fee-for-Service Plans; Funding; Goals; Heart; Human; Impairment; Inferior; Injections; Kidney; Lung; Measurement; Medical; Medical center; Medicine; Metabolic; Metabolic Diseases; Modeling; Monitor; Mus; Neoplasm Metastasis; Operating System; Pancreas; Pathogenesis; Pediatric Hospitals; Portal vein structure; Pre-Clinical Model; Rattus; Request for Proposals; Research; Research Personnel; Resolution; Rodent Model; Role; Science; Services; Structure; System; Technology; Testing; Therapeutic; Therapeutic Agents; Translating; Translations; Ultrasonography; United States National Institutes of Health; Universities; animal facility; biomarker discovery; contrast imaging; equipment acquisition; human disease; imaging system; innovation; instrument; metropolitan; novel therapeutics; pathogen; pre-clinical; right ventricular remodeling; tool; tumor; ultrasound

PROJECT SUMMARY/ABSTRACT This proposal requests funds for the acquisition of a state-of-the-art Vevo F2 high-resolution ultrasound imaging system (FujiFilm-VisualSonics). This system would be integrated into and managed by the Pre-Clinical Cardiovascular (PCC) Core facility within the Division of Cardiology/Department of Medicine at the University of Colorado Denver Anschutz Medical Campus (AMC). Due to the highly advanced technology of the Vevo F2, this system would significantly expand the current capabilities of the PCC Core and would enhance on-going, system-wide collaborations at the University of Colorado. The long-term objective of this proposal is to provide advanced ultrasound capabilities that lead to a more detailed understanding of pathophysiological mechanisms and highlight potential therapeutic strategies that could be translated into innovative treatments for human diseases. Our goal is to do the best science possible and be guided by the data. Having a Vevo F2 instrument in our PCC Core would undoubtedly help us achieve this goal. A major focus of the PCC Core to facilitate studies employing mouse and rat models of cardiovascular, pulmonary, renal, metabolic and onocologic diseases. Our ultimate goal is to translate findings made in these pre-clinical models into novel therapeutics for the treatment of devastating diseases in humans. We collaborate closely with research groups across the campus, and the entire Denver metropolitan area, to understand the roles of heart:kidney and heart:lung cross-talk in the pathogenesis of cardiorenal disease and pulmonary vascular/right ventricular remodeling. Additionally, we have collaborations focused on vascular stiffening, impaired blood flow, metabolic disease, tumor metastasis, biomarker discovery and contrast imaging in rodent models (see Figure). All of these efforts would benefit from the acquisition of a Vevo F2 instrument, which would enable state-of-the-art, non-invasive, longitudinal measurements of cardiac structure and function, renal, cardiac and pancreatic blood flow, and tumor formation in mouse and rat models. In addition, this high-definition ultrasound system would provide an invaluable tool for monitoring localized delivery of cells and therapeutic agents via intra-cardiac or portal vein injection. The Vevo F2, which has many features in common with clinical instruments, would have a tremendous impact on NIH-funded research at the University of Colorado Anschutz Medical Campus, and has the potential to facilitate translation of basic science discoveries into innovative treatments for human disease. In addition to the aforementioned collaborations, through fee-for-service arrangements, the PCC Core serves a diverse group of investigators, not only on the AMC, which has two separate animal facilities, but also in the Colorado Children's Hospital, the Rocky Mountain Regional VA Medical Center, and University of Colorado Boulder. We are also deeply committed to assisting early stage investigators obtain preliminary data to support their first NIH grant applications. For all of these studies we employ two Vevo 2100 instruments, which are located in a pathogen-free animal facility in Research Center 2 (RC2). The upgrade to the Vevo F2 is crucially needed to meet the increasing demands, and technical needs, of a multitude of projects, which have tested the limits of the Vevo 2100 instruments that we purchased in 2014. Not only is the technology of this instrument inferior to that of the Vevo F2, but the Vevo 2100 will no longer be serviced by FujiFilm-VisualSonics starting in 2023. Furthermore, the Vevo 2100 uses a Windows XP operating system, which is not compatible with the IT requirements of the University of Colorado. It is essential that we obtain a Vevo F2 to maintain and promote cutting edge biomedical research at the University of Colorado.

项目总结/摘要 该提案要求提供资金，用于购置最先进的Vevo F2高分辨率超声成像仪 系统（FujiFilm-VisualSonics）。该系统将集成到临床前 心血管（PCC）心脏病学/医学系在大学的核心设施 科罗拉多丹佛安舒茨医学院（AMC）。由于Vevo F2的高度先进技术， 该系统将显著扩展PCC核心的当前能力， 科罗拉多大学的全系统合作。这项建议的长远目标是提供 先进的超声功能，可更详细地了解病理生理机制 并强调潜在的治疗策略，可以转化为创新的治疗方法， 疾病我们的目标是尽可能做最好的科学研究，并以数据为指导。拥有Vevo F2仪器 毫无疑问，在我们的PCC核心将帮助我们实现这一目标。 PCC核心的一个主要重点是促进采用小鼠和大鼠心血管模型的研究， 肺、肾、代谢和肿瘤疾病。我们的最终目标是将这些发现转化为 临床前模型转化为治疗人类毁灭性疾病的新疗法。我们合作 与整个校园的研究小组密切合作，以及整个丹佛都会区，以了解 心肾、心肺串扰在心肾、肺疾病发病机制中的作用 血管/右心室重构。此外，我们的合作重点是血管硬化， 啮齿类动物血流受损、代谢性疾病、肿瘤转移、生物标记物发现和造影成像 模型（见图）。所有这些努力都将受益于购买Vevo F2仪器， 能够对心脏结构和功能、肾脏、心脏、心脏、 和胰腺血流以及小鼠和大鼠模型中的肿瘤形成。此外，这款高清 超声系统将提供用于监测细胞和治疗药物的局部递送的宝贵工具。 通过心内或门静脉注射给药。的 Vevo F2，它有许多共同的特点， 临床仪器，将产生巨大的影响 科罗拉多大学NIH资助的研究 安舒茨医学院，并有可能 促进基础科学发现转化为 人类疾病的创新疗法。 除了上述合作外， 通过收费服务安排，PCC核心 为不同的研究人员提供服务，不仅 AMC有两个独立的动物设施， 同样在科罗拉多儿童医院， 山区VA医疗中心和大学 位于科罗拉多博尔德。我们也深深地致力于 帮助早期调查人员获得 初步数据，以支持他们的第一个国家卫生研究院拨款 应用.在所有这些研究中，我们使用了两个 Vevo 2100仪器位于 研究中心2无病原动物设施 （RC 2）。Vevo F2的升级至关重要， 需要满足日益增长的需求， 许多项目的技术需求， 测试了Vevo 2100仪器的极限， 2014年购买。这不仅是因为这项技术 仪器不如Vevo F2，但Vevo 从2023年开始，2100将不再由FujiFilm-VisualSonics提供服务。此外，Vevo 2100使用 Windows XP操作系统，与科罗拉多大学的IT要求不兼容。 我们必须获得Vevo F2，以保持和促进尖端的生物医学研究。 科罗拉多大学。